NicOx Adds Two Blood Pressure Monitoring Studies To Naproxcinod Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Results of both blood pressure studies and two Phase III trials expected in 2008, positioning naproxcinod for mid-2009 filing.
You may also be interested in...
Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says
Facing skeptical FDA, company in partnering talks as more Phase III data with anti-inflammatory drug prove positive.
Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says
Facing skeptical FDA, company in partnering talks as more Phase III data with anti-inflammatory drug prove positive.
NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod
In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.